Citius Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview

Citius Pharmaceuticals

09/12/2022 11:19

* Citius Pharmaceuticals Inc  CTXR.OQ   CTXR.O  is expected
to show no change in quarterly revenue when it reports 
results on December 13 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Citius
Pharmaceuticals
Inc is for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $8​, above​ its last closing price
of $1.13. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.05       -0.05      -0.06     Missed  -20
 Mar. 31 2022  -0.07       -0.07      -0.05     Beat    28.6
 Dec. 31 2021  -0.06       -0.06      -0.06     Met     0​
 Sep. 30 2021  -0.04       -0.04      -0.02     Beat    50
 ​​Jun.        -0.06       -0.06      -0.06     Met     7.7
 30 2021                                                
 Mar. 31 2021  -0.08       -0.07      -0.04     Beat    46.7​
 Dec. 31 2020  0.16        0.16       -0.15     Missed  -193.7
 Sep. 30 2020  -0.11       -0.10      -0.07     Beat    33.3
 This summary was machine generated December 9 at 11:19 GMT.  All
figures in US dollars  unless otherwise stated